WO2002028416A1 - Preventives/remedies for hemolytic anemia - Google Patents

Preventives/remedies for hemolytic anemia Download PDF

Info

Publication number
WO2002028416A1
WO2002028416A1 PCT/JP2001/008572 JP0108572W WO0228416A1 WO 2002028416 A1 WO2002028416 A1 WO 2002028416A1 JP 0108572 W JP0108572 W JP 0108572W WO 0228416 A1 WO0228416 A1 WO 0228416A1
Authority
WO
WIPO (PCT)
Prior art keywords
preventives
remedies
hemolytic anemia
hemolysis
thrombomodulin
Prior art date
Application number
PCT/JP2001/008572
Other languages
French (fr)
Japanese (ja)
Inventor
Yoshitaka Hosaka
Miwa Matsumoto
Kazunori Imada
Original Assignee
Mochida Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co., Ltd. filed Critical Mochida Pharmaceutical Co., Ltd.
Priority to AU2001292308A priority Critical patent/AU2001292308A1/en
Priority to JP2002532240A priority patent/JPWO2002028416A1/en
Publication of WO2002028416A1 publication Critical patent/WO2002028416A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Hemolysis inhibitors and preventives/remedies for hemolytic anemia characterized by containing a thrombomodulin-like protein as the active ingredient. Highly safe medicinal compositions which are applicable to hemolysis caused by various factors as, in particular, preventives/remedies for acquired hemolytic anemia, remain stable in vivo, exhibit a long-lasting effect and show little side effect.
PCT/JP2001/008572 2000-09-30 2001-09-28 Preventives/remedies for hemolytic anemia WO2002028416A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001292308A AU2001292308A1 (en) 2000-09-30 2001-09-28 Preventives/remedies for hemolytic anemia
JP2002532240A JPWO2002028416A1 (en) 2000-09-30 2001-09-28 Prevention and treatment of hemolytic anemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-338308 2000-09-30
JP2000338308 2000-09-30

Publications (1)

Publication Number Publication Date
WO2002028416A1 true WO2002028416A1 (en) 2002-04-11

Family

ID=18813532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008572 WO2002028416A1 (en) 2000-09-30 2001-09-28 Preventives/remedies for hemolytic anemia

Country Status (3)

Country Link
JP (1) JPWO2002028416A1 (en)
AU (1) AU2001292308A1 (en)
WO (1) WO2002028416A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659427A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for increasing thombomodulin expression
JPH1072364A (en) * 1996-06-14 1998-03-17 Mochida Pharmaceut Co Ltd Depressant for metastasis of carcinoma
WO2000033867A1 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
WO2000066754A1 (en) * 1999-04-30 2000-11-09 Eli Lilly And Company Protein c derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659427A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for increasing thombomodulin expression
JPH1072364A (en) * 1996-06-14 1998-03-17 Mochida Pharmaceut Co Ltd Depressant for metastasis of carcinoma
WO2000033867A1 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
WO2000066754A1 (en) * 1999-04-30 2000-11-09 Eli Lilly And Company Protein c derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEERS MARK H. ET AL.: "The merck manual of diagnosis and therapy", 1999, XP002948503 *
TAKAHASHI Y. ET AL.: "Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: Comparison with low molecular weight heparin", THROMBOSIS AND HAEMOSTASIS, vol. 77, no. 4, 1997, pages 789 - 795, XP002948501 *
TAKAHASHI Y. ET AL.: "Soluble thrombomodulin purified from human urine exhibits anticoagulant effect in vitro and in vivo", THROMBOSIS AND HAEMOSTASIS, vol. 73, no. 5, 1995, pages 805 - 811, XP002948502 *

Also Published As

Publication number Publication date
JPWO2002028416A1 (en) 2004-02-12
AU2001292308A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
HUS1300023I1 (en) Anthranilamides derivatives, their use and arthropodicide compositions containing them as active ingredient
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
AU2000279625A1 (en) Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
WO2002074275A3 (en) Systems for delivering a cosmetic and/or therapeutic active to oral surfaces
DE69942154D1 (en) MEDICATION-COMPATIBLE COMPOSITION IN AEROSOL FORM
DE60124563D1 (en) FILM-CONSTRUCTING COMPOSITIONS OF PEKTIN
WO2001058412A3 (en) Extracts from residues left in the production of wine
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2004074266A8 (en) Hiv inhibiting 1,2,4-triazines
IT1320080B1 (en) COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE.
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
PT1121127E (en) PHARMACEUTICAL COMPOSITIONS ORAIS CONTAINING BUPRENORFIN
EP2308479A3 (en) Compounds and compositions for delivering active agents
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2005063194A3 (en) Method for the innoformulation of a biocompatible galenic base
WO2003018059A3 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
IL174691A0 (en) Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
WO2002000208A3 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
NZ523606A (en) Pharmaceutical compositions and methods for use
WO2002028416A1 (en) Preventives/remedies for hemolytic anemia
CA2455710A1 (en) Calcium salts with cytotoxic activity
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
WO2002019980A8 (en) Composition of vitamin c and/or vitamin a

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002532240

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase